Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer



  Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief
  Development Officer

Business Wire

CAMBRIDGE, Mass. -- June 28, 2013

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering
novel and differentiated protein-based biotherapeutics for ocular diseases,
announced today that it has appointed biologics industry veteran Karen L.
Tubridy, PharmD, as Chief Development Officer. She will be responsible for
leading and executing the company’s clinical and regulatory development
strategy, currently focused on innovative protein therapeutics for ocular
diseases. Ms. Tubridy will be a member of Eleven’s management team reporting
to Abbie Celniker, PhD, Chief Executive Officer, and she will play a key role
in advancing the clinical development of the company’s lead ocular product
candidate, EBI-005, in collaboration with Michael H. Goldstein, MD, Eleven’s
medical director and the co-director of the Cornea, External Disease and
Cataract Service group at Tufts University Medical Center.

“Karen Tubridy is joining Eleven at an exciting time in the company’s
evolution. EBI-005, the first IL-1 signaling inhibitor designed for topical
ocular administration, has just completed a Phase 1b clinical study in
patients with dry eye disease and Karen will play a key role in further
advancing the clinical development of EBI-005 based on its positive clinical
progress to-date,” said Abbie Celniker, PhD, Chief Executive Officer of Eleven
Biotherapeutics. “We look forward to leveraging Karen’s extensive global
development experience, including clinical and regulatory strategies specific
to biotherapeutic product candidates, as we continue to advance EBI-005 into
later stage clinical development.”

“Eleven’s technology has clearly demonstrated the ability to create novel
biotherapeutics with improved characteristics and therapeutic benefits, with
EBI-005 as a prime example of the promising therapeutic potential of proteins
from Eleven’s R&D engine,” said Ms. Tubridy. “I am excited to be joining
Eleven and look forward to working with the team to advance EBI-005 to its
full potential, as well as exploring other promising opportunities.”

Ms. Tubridy has more than 20 years of experience directing global clinical
programs, developing regulatory and clinical strategies, and leading
development programs of novel and first-in-class biotherapeutics. Karen
Tubridy most recently served as Senior Vice President, Clinical Development
and Medical Affairs at Inspiration Biopharmaceuticals where she successfully
led the clinical, medical and regulatory functions of the company’s lead
product candidates, OBI-1, which was acquired by Baxter in March 2013 for more
than $700 million and IB1001 which was acquired by Cangene. Before
Inspiration, Ms. Tubridy was Executive Director, Clinical Operations and
Regulatory Affairs, Translational Medicine at Alexion Pharmaceuticals and
Taligen Therapeutics (which was acquired by Alexion). Prior to Alexion, Karen
Tubridy held similar clinical operations and regulatory positions of
increasing responsibility at Syntonix Pharmaceuticals (which was acquired by
Biogen Idec), AVANT Immunotherapeutics, Wyeth, Genetics Institute and New
England Medical Center. Ms. Tubridy received her BSc and PharmD from
Massachusetts College of Pharmacy and Allied Health Sciences.

About Eleven Biotherapeutics

Eleven Biotherapeutics creates novel and differentiated biotherapeutics:
first-of-a-kind protein-based drugs with significantly improved physical,
pharmaceutical, and therapeutic benefits. The company’s AMP-Rx™ product engine
brings capabilities beyond conventional approaches for making protein
therapeutics, opening up new territory for the products to have novel
structures, enhanced biophysical properties, and more effective targeting in
disease pathways. Eleven’s success is built on designing proteins ‘fit for
purpose’ that are rationally designed to have ideal therapeutic
characteristics and result in best-in-class biotherapeutic products for a wide
range of diseases. The Cambridge, Mass.-based company was founded in 2010 by
life science investors Flagship Ventures and Third Rock Ventures and
world-renowned scientific experts. For more information, please visit
www.elevenbio.com.

Contact:

Eleven Biotherapeutics
Cameron Wheeler, PhD, 617-858-0927
cameron@elevenbio.com
or
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement